Form 8-K - Current report:
SEC Accession No. 0001104659-25-028529
Filing Date
2025-03-27
Accepted
2025-03-27 08:00:30
Documents
13
Period of Report
2025-03-25
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2510584d1_8k.htm   iXBRL 8-K 27108
  Complete submission text file 0001104659-25-028529.txt   202064

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bcli-20250325.xsd EX-101.SCH 3036
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20250325_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20250325_pre.xml EX-101.PRE 22373
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2510584d1_8k_htm.xml XML 3691
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 25775379
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)